Goldman Sachs Maintains Buy on Neurocrine Biosciences, Raises Price Target to $153
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Chris Shibutani has reaffirmed a Buy rating on Neurocrine Biosciences (NASDAQ:NBIX) and increased the price target from $134 to $153.
January 25, 2024 | 2:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs analyst reaffirms Buy rating on Neurocrine Biosciences and raises price target to $153.
The increase in price target by a reputable investment bank like Goldman Sachs typically signals a positive outlook on the company's future performance, which can lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100